(Total Views: 511)
Posted On: 06/10/2025 6:09:51 AM
Post# of 154593
Many thanks, My. That is pretty amazing, knowing that five of those patients still survived. Unfortunately, since there were 28 patients in the study and 21 had brain metastases, we can't tell from this piece if all 5 of the survivors were among the 7 who did NOT have brain metastases.
Here's the kind of thing that I found bothersome in the PRs of that era. It might or might not have been NP's influence. They write:
To rephrase, if I have it right, 75% of the patients observed a lower level of circulating cells. That means 21 of the 28. Of those 21, 18 had a huge increase in 12-month overall survival. One should think this means that the mOS of the group of 27 was markedly increased. But we don't see that number. We know only that of the people it helped, many were helped a LOT. But we don't get a grip on the overall picture.
Here's the kind of thing that I found bothersome in the PRs of that era. It might or might not have been NP's influence. They write:
Quote:
Results from the analysis showed that of the 75% of the patients who exhibited a lower level of circulating cells after leronlimab, 86% of the overall population a 3600% increase in 12-month overall survival (OS),
To rephrase, if I have it right, 75% of the patients observed a lower level of circulating cells. That means 21 of the 28. Of those 21, 18 had a huge increase in 12-month overall survival. One should think this means that the mOS of the group of 27 was markedly increased. But we don't see that number. We know only that of the people it helped, many were helped a LOT. But we don't get a grip on the overall picture.
(9)
(0)
